Back to Search
Start Over
Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
- Source :
- Cancer (0008543X); Apr2016, Vol. 122 Issue 8, p1178-1184, 7p
- Publication Year :
- 2016
-
Abstract
- <bold>Background: </bold>Biological differences between BRCA-associated breast cancer and sporadic breast cancer may warrant different adjuvant chemotherapy (ACRx) recommendations despite similar phenotypic features. A 21-gene expression profile (Oncotype DX) generates a prognostic recurrence score (RS) that predicts the ACRx benefit in patients with hormone receptor-positive breast cancer. No reports describe assay results for BRCA-associated breast cancer.<bold>Methods: </bold>A review of Memorial Sloan Kettering Cancer Center databases identified 4908 patients with hormone receptor-positive, node-negative breast cancer who underwent Oncotype DX testing between July 2006 and March 2014. BRCA1/BRCA2 carriers (cases) were identified and matched (1:2) by age at diagnosis and tumor size to noncarrier controls. Two-sample nonparametric tests were used to compare the baseline characteristics, RSs, and risk stratification between BRCA1 and BRCA2 patients. Conditional logistic regression was used to assess these differences by mutational status.<bold>Results: </bold>Fifty mutation-associated cases (19 BRCA1 cases and 31 BRCA2 cases) and 100 controls who were well matched for age (P = .9) and tumor size (P = .6) were included. BRCA1 and BRCA2 carriers had similar median RSs (P = .6) and risk category stratification (P = .3). The median RS was higher for cases versus controls (24 vs 16; P < .0001). Risk stratification also differed by mutational status (P = .0002). Cases had more high-risk disease (28% vs 7%) and intermediate-risk disease (56% vs 36%) and less low-risk disease (16% vs 57%). Cases were more likely than controls to receive ACRx (74% vs 46%; P = .002).<bold>Conclusions: </bold>Germline BRCA-associated hormone receptor-positive breast cancer may be associated with intrinsically less favorable biology. Few affected carriers have RS indicating a clear absence of benefit from ACRx. The increased use of ACRx and benefit from ACRx in BRCA carriers may mitigate otherwise inferior outcomes. [ABSTRACT FROM AUTHOR]
- Subjects :
- BRCA genes
TUMOR suppressor genes
BRCA proteins
BREAST cancer
CANCER
BREAST tumor treatment
BREAST tumors
CANCER relapse
COMPARATIVE studies
DATABASES
DISEASE susceptibility
LONGITUDINAL method
RESEARCH methodology
MEDICAL cooperation
MULTIVARIATE analysis
GENETIC mutation
PROGNOSIS
RESEARCH
RESEARCH funding
RISK assessment
SURVIVAL
LOGISTIC regression analysis
EVALUATION research
RETROSPECTIVE studies
GENE expression profiling
Subjects
Details
- Language :
- English
- ISSN :
- 0008543X
- Volume :
- 122
- Issue :
- 8
- Database :
- Complementary Index
- Journal :
- Cancer (0008543X)
- Publication Type :
- Academic Journal
- Accession number :
- 114437061
- Full Text :
- https://doi.org/10.1002/cncr.29903